Notably, in colchicine-resistant or colchicine-intolerant FMF patients, alternative treatments include biologics that neutralize the pro-inflammatory cytokine interleukin (IL)-1β directly (Canakinumab) or inhibit IL-1β-mediated activation of the IL-1 Receptor (Anakinra and Rilonacept) (24–26). This evidence concerns the gene IL1B and familial Mediterranean fever.